🇺🇸·5d agoIndustry
Emerging Data with FT819: Favorable Tolerability and Clinical Activity in Systemic Sclerosis Using Off-the-Shelf, iPSC-Derived Anti-CD19 CAR T cells without Fludarabine
Publisher
F
Fate Therapeutics
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Fate Therapeutics
- Region
- USA
- Scope
- Industry
- Published
- July 9, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on fatetherapeutics.com
Leave the platform to read the original full article on the publisher site.
Source: Fate Therapeutics
Scope: Industry
Related coverage
More related coverage
Roche Newsroom/9h ago
Roche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitis
openFDA Drug Labels/Jul 15
Drug label update: Acetaminophen Extra Strength
Official structured record identifier: 9d34abc2-3a9a-b68f-80d4-4ede1eb1e45f.
openFDA Drug Labels/Jul 15
Drug label update: Allergy Relief
Official structured record identifier: 44da36d2-1881-e779-d3a2-13ea828f9240.
Universitätsklinikum Erlangen/3h ago